COLL - Collegium Pharmaceutical downgraded to Neutral at H.C. Wainwright

• H.C. Wainwright analyst Oren Livnat downgraded Collegium Pharmaceutical ( COLL ) to Neutral from Buy without a price target.
• The company's prescription trajectories are "flat until proven otherwise," and consensus earnings estimates look too high, Livnat tells investors.
• The analyst sees the stock as "stuck" until Rx trends and Xtampza economics improve.
• Collegium Pharmaceutical SA Quant Rating stands with Buy whereas, Wall St. Analysts Rating says a Strong Buy (3 Very Bullish, 3 Bullish).
• Since the start of 2022, Collegium Pharmaceutical shares were flat, and over a period of one year, shares were down around 4% .
• Shares are currently -4.93% to $19.11 today.

For further details see: